Related Experiment Video
Updated: Jul 10, 2025
An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
Published on: July 14, 2023
Effect of azilsartan on myocardial remodeling after acute myocardial infarction
Jing Wang1, Ying Ding1, Yi-Ren Yao1
1Department of Cardiology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, 223300, China.
Insights
Azilsartan effectively improves myocardial remodeling following acute myocardial infarction (AMI). This study also suggests C1q tumor necrosis factor-associated protein 1 (CTRP1) as a potential therapeutic target for preventing cardiac remodeling post-AMI.
Area of Science:
- Cardiology
- Pharmacology
- Biomedical Research
Background:
- Acute myocardial infarction (AMI) often leads to adverse myocardial remodeling.
- Effective therapeutic strategies are needed to mitigate post-AMI cardiac dysfunction.
Purpose of the Study:
- To evaluate the efficacy of azilsartan in improving myocardial remodeling after AMI.
- To investigate the role of C1q tumor necrosis factor-associated protein 1 (CTRP1) in this process.
Main Methods:
- A randomized controlled trial involving 200 AMI patients undergoing percutaneous coronary intervention (PCI).
- Patients received either azilsartan or benazepril.
- Echocardiographic indices (LVEDV, LVEDD, LVEF) and serum CTRP1 levels were monitored over 1 year.
Main Results:
- Azilsartan significantly reduced left ventricular end-diastolic volume (LVEDV) compared to benazepril at 6 months and 1 year post-PCI.
- Serum CTRP1 levels and LVEDV decreased over time in all patients, indicating improved cardiac remodeling.
- Myocardial remodeling improvements were most evident within 6 months, with some decline thereafter.
Conclusions:
- Azilsartan demonstrates a beneficial effect on myocardial remodeling post-AMI.
- CTRP1 shows promise as a therapeutic target for managing myocardial remodeling after AMI.
Purpose:
To investigate the effect of azilsartan on myocardial remodeling after acute myocardial infarction (AMI).
Methods:
A total of 200 AMI patients under percutaneous coronary intervention (PCI) were selected from the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University from Jan 2021 to Dec 2021. The subjects were randomly divided to take either azilsartan or benazepril. Serum C1q tumor necrosis factor-associated protein 1 (CTRP1) levels were detected in all subjects after admission, and the indices of left ventricular end-diastolic volume (LVEDV), left ventricular end-diastolic diameter (LVEDD), and left ventricular ejection fraction (LVEF) were measured by using echocardiography. At the follow-up of 6 months and 1 year after PCI, the differences in CTRP1 and echocardiogram indices between the two groups were compared, and the influencing factors of myocardial remodeling after acute myocardial infarction were analyzed.
Results:
The levels of LVEDV and CTRP1 in all subjects at 6 months and 1 year after PCI were lower than those before discharge, and the LVEDV in the azilsartan group at 6 months and 1 year after PCI was lower than that in the benazepril group. An improvement in myocardial remodeling was obviously observed within 6 months after PCI, but the effect declined over time.
Conclusions:
Azilsartan can improve myocardial remodeling after acute myocardial infarction. CTRP1 may become an effective target for the prevention and treatment of myocardial remodeling after acute myocardial infarction.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
09:37Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
Published on: December 2, 2014
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers